**ABSTRACT**

**Introduction** Chronic low back pain (CLBP) is a highly prevalent and disabling condition. Identifying subgroups of patients affected with CLBP is a current research priority, for which a classification system based on pain mechanisms was proposed. Spinal manipulative therapy (SMT) is recommended for the management of CLBP. Yet, little data are available regarding its mechanisms of action, making it difficult to match this intervention to the patients who may benefit the most. It was suggested that SMT may influence mechanisms associated with central sensitisation. Therefore, classifying patients with CLBP according to central sensitisation mechanisms may help predict their response to SMT.

**Methods and analysis** This protocol describes a randomised placebo-controlled trial aiming to examine which variables linked to central sensitisation may help predict the clinical response to SMT in a cohort of patients with CLBP. One hundred patients with chronic primary low back pain will be randomised to receive 12 sessions of SMT or placebo SMT over a 4-week period. Pain intensity and disability will be assessed as primary outcomes after completing the 4-week treatment (primary endpoint), and at 4-week and 12-week follow-ups. Baseline values of two pain questionnaires, lumbar pressure pain thresholds, concentrations of an inflammatory cytokine and expectations of pain relief will be entered as predictors of the response to SMT in a multiple regression model. Changes in these variables after treatment will be used in a second multiple regression model. The reference values of these predictors will be measured from 50 age-matched healthy controls to allow interpretation of values in patients. Mixed analyses of variance will also be conducted to compare the primary outcomes and the predictors between groups (SMT vs placebo) over time (baseline vs post-treatment).

**Ethics and dissemination** Ethical approval was granted by the Fundación Jiménez Díaz Clinical Research Ethics Committee.

**Trial registration number** NCT05162924.

**INTRODUCTION**

Low back pain (LBP) is the single most important cause of disability globally, with a high proportion of patients whose pain persists or recurs. Aiming to identify patient profiles that respond more favourably to specific treatments and their prognosis, recent investigations highlight the importance of identifying subgroups among people with chronic LBP (CLBP). One of the proposed classification systems stratifies patients into specific subgroups according to pain mechanisms (nociceptive, neuropathic or central sensitisation). It has been suggested that a large proportion of patients with CLBP presents chronic primary pain, which has been linked to altered nociceptive processing. Among the phenomena that may underlie this aberrant processing, central sensitisation (CS) is likely the predominant...
mechanism,12 13 and its involvement in CLBP deserves further research.14

One of the currently recommended interventions for the management of CLBP is spinal manipulative therapy (SMT).15 16 However, not all patients have an identical response.17 There are insufficient data to determine which CLBP subgroups respond better to this intervention.18 19 This may be so because the analgesic mechanisms are still largely unknown. It was proposed that the pain-relieving effects of SMT partly rely on segmental pain inhibition processes.20 These processes influence temporal summation of pain21 22 or primary and secondary hyperalgesia,23 24 which may be measured to identify patients with a CS phenotype. Further, emerging data from animal and human studies support the hypothesis that SMT modulates the inflammatory response, influencing inflammatory cytokines.25–28 Cytokines can induce neuroinflammation, which may mediate the development of CS29 30 in the transition towards chronic pain.8 31 SMT may thus relieve CLBP by impacting mechanisms linked to CS.24 32–34

Altered pain sensitivity in a specific musculoskeletal region may indicate nociceplastic pain,12 35 36 likely reflecting CS.13 Abundant studies have reported that a subgroup of patients with CLBP demonstrate segmental mechanical hyperalgesia, assessed via lower pressure pain thresholds (PPTs) in low back or lower extremity areas, which may be measured to identify patients with a CS phenotype.37 Changes in pain sensitivity are not confined to lumbar segments but rather may be present in remote anatomical locations38–42 when compared with healthy controls.37–42 Changes in threshold (PPTs) in low back or lower extremity areas, mechanical hyperalgesia, assessed via lower pressure pain thresholds in a subgroup of patients with CLBP demonstrate segmental hyperalgesia.5 6 53 54 The release of inflammatory cytokines, including the proinflammatory tumour necrosis factor alpha (TNF-α), was identified as a potential mechanism supporting this phenomenon.26 30 37 38 Studies have shown an association between proinflammatory cytokines and CLBP,39–42 suggesting that these may serve as a reliable biomarker to identify patients with a CS phenotype.

The classification of mechanism-based pain phenotypes is a complex and controversial task,35 63 64 for which a variety of clinical, inflammatory, psychological and psychophysical constructs must be considered.9 65 Although CS may influence changes in pain sensitivity induced by SMT,32 pain phenotyping has been scarcely applied to manual therapy research.66 Therefore, the response of this subgroup of patients to SMT has yet to be assessed. The aim of this clinical trial is to investigate whether variables associated with a CS phenotype may help predict the response to SMT. The specific objectives are: (1) to identify the clinical, psychological, psychophysical and inflammatory variables linked to CS in a cohort of patients with CLBP; and (2) to examine which of these variables predict the clinical response to SMT.

METHODS
Experimental design and setting

The study consists of a mechanistic randomised placebo-controlled clinical trial with a mixed experimental design, whose objective is to assess which variables linked to CS in patients with chronic pain can predict the response of patients with CLBP to SMT (figure 1). This protocol is reported according to the guidelines for clinical trial protocols Standard Protocol Items: Recommendations for Interventional Trials.67 Starting in November 2021, 150 participants will be recruited through the Madrid College of Chiropractic (MCC) teaching clinic in San Lorenzo de El Escorial (Spain). This includes 100 patients with CLBP and 50 healthy participants. The MCC clinic is a primary care setting specialised in spine care, including chiropractic and physical therapy services. Clinical, psychological, psychophysical and inflammatory variables will be measured in patients with CLBP, which will be exposed to either SMT or a placebo SMT for 12 visits over a 4-week period. A group made up of 50 age and sex-matched healthy volunteers will be used to determine the reference values of the same psychological, psychophysical, and inflammatory variables in a healthy population and compare them with the clinical population, before and after exposure.

Selection criteria

An investigator with over 20 years of clinical experience will be responsible for the selection of participants. To be eligible to participate in the study, patients must be 18–70 years old, receive a diagnosis of chronic primary LBP of at least 3-month duration, with or without leg pain (according to a clinical examination carried out at the MCC; see figure 2A). If pain affecting the low back or lower limb is suspected to be predominantly of neuropathic origin, the patient will be excluded.12 Additionally, patients will be excluded from the study if they present any of the following criteria: evidence of specific pathology as the cause of their CLBP, diagnosis of mental illness (with the exception of anxiety and depression, as these conditions are frequently comorbid with CLBP68 69 and may
suggest a CS phenotype, presence of pain of equal or higher intensity affecting any other body region, use of corticosteroids, opiates or anti-cytokine medication, pregnancy, lumbar fusion surgery or recent laminectomy, and having received chiropractic SMT in the 12 months prior to the beginning of the study.5 49,50 51

Figure 1 CONSORT diagrams of the randomised clinical trial proposed, including the healthy participants’ control arm. ANOVAs, analyses of variance; BDI-II, Beck Depression Inventory II; CLBP, chronic low back pain; CONSORT, Consolidated Standards of Reporting Trials; CSI, central sensitisation inventory; GAD, Generalized Anxiety Disorder; PCS, Pain Catastrophizing Scale; PPTs, pressure pain thresholds; SMT, spinal manipulative therapy; TNF-α, tumour necrosis factor alpha.

A cohort of healthy volunteers will be recruited to be used as a reference for the psychological, psychophysical and inflammatory variables collected in the sample of patients with CLBP. They will be age- and sex-matched to the patients allocated to the group receiving SMT. Individuals meeting the following criteria are eligible to

Figure 2 Study protocol for the clinical trial. The recruitment process is illustrated in (A), the collection of variable data during the initial examination is depicted in (B,C), (D) Illustration of the treatment protocol and (E,F) the collection of variable data at the end of the 4-week treatment (ie, primary endpoint), and (G) the collection of pain intensity and disability data at the 4-week and 12-week follow-ups. BDI-II, Beck Depression Inventory II; CSI, Central Sensitisation Inventory; GAD, Generalized Anxiety Disorder; LBP, low back pain; ODI, Oswestry Disability Index; PCS, Pain Catastrophizing Scale; PPTs, pressure pain thresholds; SMT, spinal manipulative therapy.

participate: being 18–70 years old; presenting no current or chronic pain condition, as well as not having received any diagnosis of a systemic, inflammatory, neurological or psychiatric condition.

**Randomisation, concealed allocation and blinding**

A computer application (random-number generator) will be used to generate a balanced randomisation sequence. Participants will be allocated in a 1:1 ratio to the intervention (SMT) or placebo arms following the chronological order of recruitment. Patients, outcome assessors and statistician will be blinded to group allocation. To confirm the efficacy of the patients’ blinding, participants will respond in three occasions to the questions: ‘Do you think that the treatment you have received is a real chiropractic treatment for back pain?’; and ‘On a Numerical Rating Scale of 0–100, please rate the degree of certainty for having received a real chiropractic treatment’ (with 0 being total uncertainty and 100 being absolute certainty).

Additionally, to avoid biases in the reporting of patient-reported outcome measures and to blind the investigator delivering the interventions, participants will provide these data via electronic questionnaires without the presence or interference of any investigator.

**Interventions**

Both real and placebo SMT will be delivered by a chiropractor with 20 years of experience who is part of the research team (CG-M). Two real SMTs will be performed with the patient positioned in the lateral decubitus position (once on each side), by applying a high-velocity, low-amplitude force on the manipulated segment, with the aim of generating at least one joint cavitation (associated with an audible sound). For this, the chiropractor will use the hypothenar surface or the last phalanx of the second and/or third fingers of the hand to contact the spinous process of the vertebral segment with the most intense clinical pain (see online supplemental figure 1A), as identified in the initial patient examination. In case of not perceiving a cavitation or satisfactory joint movement, SMT may be repeated once on each side. Therefore, all participants in the SMT arm will receive a minimum of two and a maximum of four SMT thrusts. Participants in the placebo arm will receive a validated sham SMT that is very similar to SMT. The patient is positioned in the same lateral decubitus position, with the lower leg in extension and the upper leg in flexion, and an unintended force is applied bilaterally to the gluteal region (online supplemental figure 1B). The number of real or placebo SMT attempts resulting in joint cavitation will be recorded. Participants in both groups will receive three treatment sessions per week for 4 weeks (see figure 2). Healthy volunteers will receive no intervention during the same time frame of 4 weeks (see figure 3).

**Outcome variables**

**Primary outcomes**

Patients will rate their current CLBP intensity, as well as the average, minimum and maximum pain throughout the preceding 7 days or since the time of the previous session, once the study is underway, using a Numerical Rating Scale between 0 (no pain) and 100 (maximum pain imaginable). Average pain intensity will be used as a primary outcome for all statistical analyses. The primary endpoint will be the change from baseline at the completion of the 12 sessions of SMT. For the follow-up, average pain intensity will be assessed 4 and 12 weeks after the completion of the trial.

Disability caused by CLBP will also be assessed as a primary outcome. After completing the case history, patients will fill out the Oswestry Low Back Disability Index Questionnaire. The questionnaire will also be
completed after the 12th treatment session (primary endpoint), and at subsequent 4-week and 12-week follow-ups.

Secondary outcomes
Five topics were identified to discriminate pain mechanisms between groups of patients, including CS mechanisms: clinical examination, questionnaires, quantitative sensory testing, laboratory tests and imaging tests. For the present study, all categories will be considered except the last one, which will only be used to rule out pain of suspected neuropathic or nociceptive aetiology. Variables belonging to these categories will be assessed for exploratory purposes and five of them will be examined as predictors of the response to SMT (two questionnaires, one quantitative sensory testing variable, one laboratory test variable and the expectations of pain relief).

Clinical examination variables
Data on the characteristics of the patients’ CLBP will be collected at baseline for exploratory purposes: CLBP trajectory (duration and frequency) and localisation. The duration of CLBP will be calculated as the number of months since the onset of the first episode of LBP. As for pain frequency, participants’ CLBP trajectory will be classified as either fluctuating or episodic, depending on whether they recall asymptomatic periods of at least 4 weeks (episodic) or not (fluctuating). For pain localisation, patients will also draw the area affected by their pain on a tablet, using an application (Symptom Mapper) that will allow to calculate the degree of pain widespreadness. Additionally, CLBP will be classified as either proportionate or disproportionate to the degree or nature of the injury or pathology, with a discrete or diffuse distribution, according to criteria that were defined in the literature.

A diffuse rather than a discrete pain distribution was identified as a key criterion of a CS phenotype. Also, classifying symptoms as proportionate (or not) was proposed to differentiate nociceptive pain from CS mechanisms. The pattern of pain distribution and the provocation and response to aggravating and palliative factors will be assessed during case history and physical examination. This will be complemented with information provided by diagnostic imaging when available.

Finally, other variables will be reported such as the intake of pain medication compatible with the selection criteria, both at baseline and after treatment. Similarly, whether the patient regularly smokes will be documented, since smoking has been associated with increased serum levels of proinflammatory cytokines. The average number of hours of sleep will also be recorded, as it may help predict pain patterns. Additionally, the presence of any chronic condition (including pain) that is comorbid with the CLBP will be recorded for exploratory purposes.

Questionnaire variables
The Pain Catastrophizing Scale (PCS) and CSI will be completed before the beginning of the treatment (baseline) and at a single follow-up after the 12th treatment session (see figure 2B and F). The PCS will be used to identify specific pain cognitions that are frequently present in patients with a CS phenotype; this measure will be used to evaluate the association of CLBP with psychosocial factors described by Smart et al. When combined with a clinical presentation suggestive of CS, the CSI is a useful tool to identify patients with certain pain mechanisms compatible with CS, particularly when using the cut-off value of 40 points. Both these scores will be examined as predictors due to their intrinsic association with a CS phenotype.

In addition, the Beck Depression Inventory II (BDI-II) and the Generalized Anxiety Disorder Scale (GAD) Questionnaires will be used to screen and quantify symptoms of depression and anxiety. The scores in these questionnaires will be measured both at baseline and after the 12th treatment session for exploratory purposes. We will examine whether these variables are associated with the primary outcomes. Pre/post-reference values of all questionnaires (PCS, CSI, BDI-II and GAD) will be taken from the healthy control participants in the same time frame (figure 3).

Quantitative sensory testing variables
Quantitative sensory testing based on the German protocol will be performed with the aim of evaluating pain thresholds and sensitivity (see figure 2C). Testing will consist of the exploration of the PPTs in deep tissues (figure 4), using an algometer (Wagner Force Dial FPX, Greenwich, Connecticut, USA). In addition, patients will rate the intensity of the first stimulus above threshold, using a Numerical Rating Scale 0–100. PPTs will be assessed by two interns completing their Master’s in Chiropractic degree, after 3 months of training and pilot data collection. One of the two outcome assessors will be randomly assigned to each patient to perform both baseline and follow-up measurements. Two measurements will be taken bilaterally at a rate of about 50 kPa/s, and the arithmetic mean of both the thresholds and sensitivities reported calculated. Two consecutive measurements provide excellent reliability when assessing both populations with and without LBP, while performing two repetitions per side of the lower back was proposed to optimise inter-session reliability. PPTs will be performed over muscle tissue in four different locations bilaterally. Primary pain will be assessed 2.5 cm lateral to the spinous process in the erector spinae of the vertebral segment with the highest clinical pain intensity indicated by the patient and verified by palpation (figure 4). Manual palpation will be performed to confirm that the selected segment either reproduces clinical pain or is the closest to the area (or to the centre) of CLBP symptoms. This will allow to assess the area of primary pain or hyperalgesia (segmental sensitivity). In addition, PPTs will be measured on both lower limbs in the dermatome corresponding to the segment of highest clinical pain intensity (dermatomal sensitivity), in the erector spinae four to six segments cranial to the

most painful lumbar segment (heterosegmental sensitivity in a non-symptomatic segment: secondary hyperalgesia) and in a remote location in both thenar eminences (widespread sensitivity). PPTs will be assessed during the initial examination for baseline and after the final treatment session (see figure 2C and E). Reference values will be taken in healthy volunteers in the same locations as the participants with CLBP receiving SMT (lumbar segmental, dermatomal, heterosegmental, widespread) at baseline and after 4 weeks (figure 3).

**Laboratory test variables: TNF-α as an inflammatory biomarker in urine**

Before initiating the first treatment session and on the day of the last treatment session, urine samples will be collected (first morning micturition) and stored at −20°C (see figure 2B and F). Additionally, the first morning micturition will be collected twice from healthy individuals in the same time frame (two samples with a 4-week delay; see figure 3). Samples will be deidentified by using only the participant’s ID code, and the laboratory technicians will be blinded to group allocation. Urine concentrations of TNF-α will be quantified for each sample using specific ELISA for TNF-α following manufacturer’s instructions. The cytokine-to-creatinine ratio will be calculated to correct for differences in urine volumes. TNF-α values, including urinary concentrations, were found to be elevated in patients with CLBP and may respond to a treatment based on SMT.

**Expectations**

Before initiating treatment, each participant will be asked to rate their expectations of pain relief upon completion of the study. To do this, a verbal evaluation will be provided using a Visual Analogue Scale with the descriptors −100, equivalent to ‘total pain relief’; 0, equivalent to ‘no change’; up to +100, equivalent to ‘maximum pain increase’. Such an assessment of patients’ expectations allows to identify their contribution as part of the placebo response, which was found to predict the response to treatment for chronic pain.

**Adverse events reporting**

At the beginning of every SMT or placebo treatment sessions, patients will inform whether they have suffered any adverse effects that they feel could be related to the treatment received via an electronic questionnaire. Adverse effects will be classified into four categories most frequently reported after lumbar SMT as identified in a clinical trial: muscle stiffness, increased pain, radiating discomfort and others. In addition, patients will indicate whether they were triggered immediately, up to 24
hours, or more than 24 hours after the previous session, whether their duration was of minutes, hours (<24 hours), between 24 and 48 hours, or longer than 48 hours, and according to their intensity (very mild, mild, moderate, severe, very severe). The reporting of adverse events will be monitored by an investigator not involved in clinical care or examination. A 30-point increase in pain intensity or the reporting of moderate-to-severe adverse events in three consecutive visits will raise the alarm and the patient will be interviewed to determine whether care should be interrupted.

Healthy volunteers will be contacted 1 week prior to the follow-up appointment to rule out any of the following criteria that would exclude them from the follow-up: presence of pain or other symptoms for >7 days, trauma or injury, initiating a new treatment or receiving a diagnosis compatible with the exclusion criteria. In addition, if the participant reports any pain or taking any pain medication within 24 hours of the follow-up, this session will be postponed for up to 1 week.

Procedures
Candidates interested in participating in the study will initially complete a form with the selection criteria (online supplemental appendix 1). If the criteria are met, patients will schedule an appointment at the MCC clinic where they will read and sign a participant information sheet and the informed consent (online supplemental appendices 2 and 3). Subsequently, patients will undergo a clinical examination (consisting of a case history and physical examination) to confirm the diagnosis of chronic primary LBP, during which all outcomes will be collected, except for the urine sample that will be provided before the first treatment session. Patients will then participate in 12 treatment sessions divided into three weekly sessions for 4 weeks. All outcome measures will be reassessed at the 12th and last treatment session (ie, the primary endpoint). After completing data collection at the primary endpoint, patients allocated to the placebo arm will be offered the possibility of receiving the ‘real’ SMT, free of charge, at the MCC. In addition, all patients will be contacted for the follow-up of CLBP intensity and disability, 4 and 12 weeks after the primary endpoint (figure 2G). Meanwhile, healthy volunteers will participate in two visits (baseline and follow-up after 4 weeks) when all relevant outcomes will be assessed (figure 3). The study will have total estimated duration of 1 year.

Sample size calculation
To determine the ideal number of participants, the second aim to identify the variables linked to a CS phenotype that could help predict the response to treatment based on SMT for CLBP was considered. A multiple regression analysis will be performed using five independent variables described in the Statistical analysis section as predictors. These variables include baseline values of local PPTs, urinary concentrations of TNF, scores in PCS and CSI questionnaires, and a priori expectations of pain relief. For each predictor variable, it is recommended estimating about 10 sample elements; therefore, we predict that a sample size of 50 patients per group will be necessary. A total of 110 patients will be recruited, accounting for an estimated dropout rate of 5%–10%.

Regarding the primary outcome variables, a reduction in pain intensity and disability after 1 month in patients who receive 12 sessions of SMT compared with placebo will be expected. We aim to detect small-to-moderate effects since it is a 1-month intervention in patients with chronic pain unresolved by other treatments over at least 3 months. Therefore, based on an effect size of f=0.175, an alpha of 0.05, a power of 0.8 for two groups and two repeated measures (baseline and primary endpoint), and a correlation between the repeated measures of 0.5, the size of the necessary sample is 34 patients per group, thus a total of 68 patients to detect statistically significant changes in clinical pain and disability. Therefore, the analysis based on the regression model to predict the clinical course provides with a large enough size for identifying small between-group differences.

Statistical analysis
The normal distribution of the data will be verified using the Kolmogorov-Smirnov test. Data deviating from normality will be transformed to obtain a normal distribution before being entered into the data analysis. In order to interpret the values in outcomes measured in patient groups, these will be compared with reference values obtained from the healthy controls to the CLBP group receiving SMT. This will allow characterising the patients’ groups (aim 1) to determine whether they show increased psychological symptoms, pain sensitivity and hyperalgesia as well as increased TNF-α levels compared with a reference healthy population. A series of mixed analyses of variance (ANOVAs) will be performed to examine differences in PPTs, urinary TNF-α levels, PCS, CSI, BDI-II and GAD scores before and after the 4-week treatment period between the three groups (control, SMT and placebo). To test a priori hypotheses, significant effects will be decomposed using planned comparisons. For the rest of the effects, Tukey’s honest significance test (HSD) will be used for testing any pairwise comparisons between group means.

Pearson’s product-moment correlation analyses will be carried out to examine the association between the primary and secondary variables that demonstrate significant effects between groups over time. Subsequently, two multiple regression models will be used to examine the predictors of improvement in clinical pain and disability over time in patients who have received SMT (aim 2). The variables used as predictors for this analysis will be: baseline PCS and CSI score, baseline PPTs in the primary pain region, baseline TNF-α levels and (baseline) expectations of pain relief. In addition, in another regression model, the changes (delta) in these variables (except expectations of pain relief, which are only measured a
priori) after 4 weeks of treatment will be used as predictor variables. This is done to identify the variables most associated with clinical evolution to answer the mechanistic question.

The primary outcome variables (clinical pain intensity and disability) will be compared between groups (SMT vs placebo) over time at the primary endpoint using mixed ANOVAs. Average pain intensity since the last treatment visit and in the 7 days prior to the initial visit will be the pain variables used for statistical analyses. With an exploratory objective, the secondary variables (PCS, CSI, BDI-II, GAD scores, PPTs, degree of pain widespreadness, urinary cytokine levels, number and severity of reported adverse effects, presence of leg pain, pain medication use) will be compared between groups (SMT vs placebo) over time (baseline and post-treatment) using mixed ANOVAs. To test a priori hypotheses, significant effects will be decomposed using planned comparisons. For the rest of the effects, Tukey’s HSD will be used for testing any pairwise comparison between group means.

As recommended by White et al, efforts will be directed towards following up all participants for every time point. An intention-to-treat analysis including all randomised study participants with a baseline endpoint assessment will be performed. The use of mixed-model ANOVA allows to include all study participants with a lower attrition bias while handling missing data using maximum likelihood estimations. Further, a per-protocol analysis will be also performed excluding study participants who voluntarily drop out from the study, develop a severe adverse reaction (increase in >30 points average pain intensity associated with treatment) or fail to attend three consecutive visits, or more than 2 treatment weeks. Finally, in order to test whether the data are not missing at random, a sensitivity analysis will be conducted to explore the effect of attrition.

Data management and monitoring

All data will be collected at the MCC teaching clinic of the Real Centro Universitario María Cristina. The clinic uses a password-protected computer app that generates a patient file number linked to their clinical and personal data. This file number will be connected to a unique patient ID code made up of three numbers and a letter. This ID code will be used to deidentify all clinical trial data. Only the investigator involved in delivering care will have knowledge of which clinic file number corresponds to which study ID code. The participants’ selection, information, consent forms and outcome measures collected in paper format will be securely stored in a file cabinet at the MCC clinic. Patient-reported outcome measures will be collected electronically using the study ID code to complete a Google form (Google LLC, Mountain View, CA, USA). Both paper and online data will be transferred to a password-protected spreadsheet, only accessible to the principal investigator. Data will be stored deidentified for 25 years after final publication. The dataset will be made available after publication of the trial, upon request to the corresponding author.

Patient and public involvement

The local chiropractic patient and professional associations (Asociación Española de Usuarios de Quiropráctica and Asociación Española de Quiropráctica) have been involved throughout the study in the recruitment process and in promoting the trial. Upon completion of the study, the results will be disseminated to the patient community in the general assembly of the patient association, as per a formal agreement with the investigators.

Ethics and dissemination

This clinical trial obtained ethical approval from the Fundación Jiménez Díaz Clinical Research Ethics Committee. All participants in the study will sign an informed consent form. Any amendment to the protocol will be communicated to the ethics review board and the clinical trial registry. The results of the study will be submitted for publication in peer-reviewed journals and disseminated via scientific conferences and presentations directed to the professional and patient associations.

DISCUSSION

The stratification of patients with CLBP is essential to better understand the needs of individual patients and provide targeted treatment. A mechanism-based classification is a promising avenue to match patients with the care that is best suited with their CLBP mechanism. However, there is an ongoing debate regarding the definition of these subgroups and the best available tools to diagnose them.5 12 35 63 64 The most recent guidelines for the management of CLBP in both a primary care and a physiotherapy setting recommend SMT as one of the first options for care.65 66 Nonetheless, it is not yet possible to identify which patients may benefit the most. The current study describes a protocol for a mechanistic randomised placebo-controlled trial that may contribute to unveil the CS-related mechanisms involved in CLBP relief by SMT. The main objective of the proposed trial is to provide some insight on potential mechanisms of SMT that may be particularly relevant for a subgroup of patients with CLBP. Grasping these mechanisms may help better guide conservative care for patients with CLBP by assessing clinical, neurophysiological, cognitive and/or biochemical variables at baseline.

Strengths and limitations

The main strength of the current study is the robust design using a validated placebo and assessing the blinding of participants, while ensuring the blinding of outcome assessors, statistician and laboratory technician. Moreover, the investigator delivering care will be blinded to the patients’ progress. This will reduce biases that are typically introduced in manual therapy trials. Additionally, the use of a control group will help determine reference

values and their stability in a healthy population, which has not been readily reported, particularly concerning urinary levels of inflammatory cytokines. Further to this, the multidimensional approach to defining central sensitisation and the mechanisms leading to it may render relevant data in better defining pain mechanisms involved in CLBP.

Regarding potential limitations, having only one clinician may limit the generalisability of the SMT effects. However, it also has the advantage of standardising the interventions and reducing variability in the procedures. It should also be noted that although blinding the investigator providing care is desirable, it is impossible in manual therapy trials, including the present study. As the sham and real SMT have a high degree of similarity, effective blinding of participants is feasible. The inability to distinguish the placebo from the real treatment is desirable to limit interpretation bias, particularly in a mechanistic trial as in the present study. However, the sham SMT may rely on specific mechanisms that overlap with those of real SMT, leading to treatment effects. Accordingly, the sham SMT should not be considered as an inert placebo and the lack of between-group differences should be interpreted with caution, with a potential risk for type II errors.

**Twitter** Carlos Gevers-Montoro @CarlosGeversDC

**Acknowledgements** Figures 2 and 3 were created with biorender.com.

**Contributors** All authors contributed to the design of this protocol. CG-M and MP conceptualised and designed the protocol, except for every aspect related to laboratory analyses, which were conceptualised by AO-DM. The protocol was drafted by CG-M, and revised by MP and AO-DM. The statistical analysis was designed by MP. CG-M was responsible for ethical committee approval.

**Funding** This work was supported by the Chaire de Recherche Internationale en Santé Neuromusculosquelettique. CG-M’s work was supported by ECCRE. MP’s work was supported by the Fonds de Recherche du Québec en Santé (FRQS). MP’s work was supported by AO-DM’s work was supported by the Fondation de Recherche en Chiropratique du Québec and the Excellence (ECCRE). AO-DM’s work was supported by the Fonds de Recherche du Québec en Santé (FRQS).

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

**Patient consent for publication** Obtained.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: [http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/).

**ORCID iDs**

Carlos Gevers-Montoro http://orcid.org/0000-0001-5031-8808

Mathieu Piché http://orcid.org/0000-0003-4171-2226

**REFERENCES**


62 Hoehg M, Schmid AB, Hansson P, et al. Not being able to measure what is important, does not make things we can measure important. Pain 2022;163:6864.


